Wisp debuts its first-ever exclusive over-the-counter weight-loss supplement, designed to promote women's metabolic health. Wisp introduces personalized, online consultations with access to four weight care solutions, including GLP-1 medications, to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis. With over 1.
2 million patients, Wisp Now Also Bolsters its Menopause Solutions, Empowering Women Through All Major Stages of Their Healthcare Journey VANCOUVER, BC and TORONTO , Oct. 17, 2024 /PRNewswire/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF ) (" WELL " or the " Company "), a digital healthcare company focused on improving health outcomes through technology and empowering healthcare providers globally, is pleased to announce the launch of a new weight care vertical by its majority-owned subsidiary, Wisp, the largest dedicated women's telehealth provider in the U.
S. With Wisp now serving over 1.2 million patients, this expansion represents a pivotal step forward in addressing critical health needs related to hormonal imbalances and weight management for women.
Through this launch, Wisp introduces personalized, online consultations with access to four weight care solutions, including GLP-1 medications, to support women struggling with hormonal conditions such as perimenopause, menopause, Polycystic Ovary Syndrome (PCOS), and endometriosis. Additionally, Wisp debuts its first-e.
